Abstract
Cannabinoid CB-1 receptors have been the focus of extensive studies since the first clinical results of rimonabant (SR141716) for the treatment of obesity and obesity-related metabolic disorders were reported in 2001. To further evaluate the properties of CB receptors, we have designed and efficiently prepared a series of oxadiazole-diarylpyrazole 4-carboxamides. Six of the new compounds which displayed high in vitro CB1 binding affinities were assayed for binding to CB2 receptor. Noticeably, 5-(4-bromophenyl)-3-(5- tert-butyl-1,3,4-oxadiazol-2-yl)-1-(2,4-dichlorophenyl)- N-phenyl-1 H-pyrazole-4-carboxamide ( 12q) and 5-(4-bromophenyl)-3-(5- tert-butyl-1,3,4-oxadiazol-2-yl)-1-(2,4-dichlorophenyl)- N-(pyridin-2-yl)-1 H-pyrazole-4-carboxamide ( 12r) demonstrated good binding affinity and decent selectivity for CB1 receptor (IC 50 = 1.35 nM, CB2/CB1 = 286 for 12q; IC 50 = 1.46 nM, CB2/CB1 = 256 for 12r).
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
